Undiscovered Gems On None Exchange For November 2024

As global markets experience broad-based gains with smaller-cap indexes outperforming their larger counterparts, investors are paying close attention to economic indicators such as the recent drop in U.S. initial jobless claims and stabilizing mortgage rates that have bolstered market sentiment. In this environment, identifying stocks that offer strong fundamentals and growth potential can be particularly rewarding, especially those that remain under the radar despite favorable conditions for small-cap companies.

Top 10 Undiscovered Gems With Strong Fundamentals

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
SHL Consolidated Bhd	NA	15.25%	15.00%	★★★★★★
Hubei Three Gorges Tourism Group	11.32%	-9.98%	7.95%	★★★★★★
Göltas Göller Bölgesi Cimento Sanayi ve Ticaret	18.55%	49.61%	71.72%	★★★★★★
Ovostar Union	0.01%	10.19%	49.85%	★★★★★★
Power HF	2.91%	-6.25%	-22.13%	★★★★★★
Impellam Group	31.12%	-5.43%	-6.86%	★★★★★★
Tianyun International Holdings	10.09%	-5.59%	-9.92%	★★★★★★
Ellaktor	73.80%	-24.52%	51.72%	★★★★★☆
A2B Australia	15.83%	-7.78%	25.44%	★★★★☆☆
Wilson	64.79%	30.09%	68.29%	★★★★☆☆

Click here to see the full list of 4631 stocks from our Undiscovered Gems With Strong Fundamentals screener.

We'll examine a selection from our screener results.

Dodla Dairy (NSEI:DODLA)

Simply Wall St Value Rating: ★★★★★★

Overview: Dodla Dairy Limited, along with its subsidiaries, focuses on the production and sale of milk and milk products both in India and internationally, with a market capitalization of ₹73.62 billion.

Operations: Dodla Dairy generates revenue primarily from the sale of milk and milk products, totaling ₹34.44 billion. The company's financial performance is influenced by its ability to manage production costs and optimize sales in both domestic and international markets.

Dodla Dairy, a nimble player in the dairy sector, has shown robust performance with earnings surging by 58.7% over the past year, outpacing the industry average of 17.4%. The company recently reported net income of INR 633.76 million for Q2 compared to INR 436.02 million last year, with basic earnings per share climbing to INR 10.54 from INR 7.33. Dodla's strategic acquisition of land in Maharashtra aims to bolster its operational efficiency and expand its value-added product portfolio, signaling potential growth avenues ahead as it continues to enhance its market presence and profitability metrics like debt reduction from 37.8% to just 2.3%.

• Delve into the full analysis health report here for a deeper understanding of Dodla Dairy.

• Explore historical data to track Dodla Dairy's performance over time in our Past section.

Innova Captab (NSEI:INNOVACAP)

Simply Wall St Value Rating: ★★★★★★

Overview: Innova Captab Limited is an integrated pharmaceutical company involved in the research and development, manufacture, distribution, and marketing of drugs both in India and internationally, with a market cap of ₹58.10 billion.

Operations: Innova Captab generates revenue primarily from its Drugs and Pharmaceutical Products segment, amounting to ₹11.78 billion.

Innova Captab, a nimble player in the pharmaceutical sector, has shown promising financial health with its interest payments comfortably covered by EBIT at 40.4 times. The company's net debt to equity ratio of 26.9% is satisfactory, reflecting prudent financial management as it reduced from 65.4% over five years. Recent earnings growth of 53% outpaced the industry average of 37.9%, highlighting robust performance and potential for further expansion, especially with their new Jammu facility receiving a manufacturing license this November. Despite not being free cash flow positive currently, Innova's profitability ensures a stable runway ahead.

• Click to explore a detailed breakdown of our findings in Innova Captab's health report.

• Assess Innova Captab's past performance with our detailed historical performance reports.

Kaken Pharmaceutical (TSE:4521)

Simply Wall St Value Rating: ★★★★★★

Overview: Kaken Pharmaceutical Co., Ltd. is engaged in the production, marketing, and sale of medical products, medical devices, and agrochemicals both in Japan and internationally with a market capitalization of approximately ¥168.96 billion.

Operations: Kaken generates revenue primarily from its Pharmaceutical Business, contributing ¥84.81 billion, while its Real Estate segment adds ¥2.44 billion.

Kaken Pharmaceutical, a nimble player in the pharmaceutical sector, has shown remarkable earnings growth of 415% over the past year, outpacing industry peers significantly. With a debt-to-equity ratio now at 2.5 from 3.1 five years ago, it seems financial health is improving alongside high-quality earnings. The company’s P/E ratio stands attractively at 9.3x compared to Japan's market average of 13.6x, suggesting potential undervaluation. Despite these strengths, future prospects appear challenging with forecasts indicating an average annual earnings decline of 56% over the next three years, highlighting potential headwinds ahead for investors to consider carefully.

• Navigate through the intricacies of Kaken Pharmaceutical with our comprehensive health report here.

• Review our historical performance report to gain insights into Kaken Pharmaceutical's's past performance.

Next Steps

• Embark on your investment journey to our 4631 Undiscovered Gems With Strong Fundamentals selection here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com